Danaher Corporation
Large Cap · Healthcare · Diagnostics & Research
$202.44−$1.45 (-0.71%)
Danaher Corporation
Large Cap · Healthcare · Diagnostics & Research
$202.44−$1.45 (-0.71%)
Stock analysis
Get the AI take on DHR
Track it to unlock the price chart, verdict and what could change it.
- ✓Live price chart
- ✓A clear accumulate, trim or avoid call
Free to track. No card required.
Stock Fundamentals & Key Indicators
52-week range
Low$160.93
High$242.80
Today $202.44
RSI (14)
55.3Neutral
03070100
Overall score
56/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
Analyst Rating and Sentiment
Analyst price targets
Lowest
$195
Current price
$202.44
Median target
$230
Highest
$310
LowHigh
Operating Record
Revenue
Business mix
Jun 30, 2026Diagnostics40.1% · $10.1B
Biotechnology30.1% · $7.5B
Life Sciences29.8% · $7.5B
Geographic mix
Jun 30, 2026North America58.0% · $10.3B
Western Europe34.9% · $6.2B
Other Developed Markets7.1% · $1.3B
What's working
- Debt / equity: Light borrowing means a rough patch wouldn't threaten the balance sheet.
- Current ratio: What's on hand comfortably covers the bills due over the next year.
What to watch
- Debt exceeds cash by $23.5B, increasing balance-sheet pressure, a warning sign.
- Forward P/E: The price already assumes strong earnings growth that still has to show up.
What the market charges
Forward P/E
Needs attention · 17% above avg
22.88x
Price / sales
Reasonable · Priced reasonably against its revenue
5.67x
Price / FCF
Reasonable · Priced a bit rich against its cash flow
26.04x
EV / EBITDA
Reasonable · Operating earnings make this price a stretch but plausible
20.66x
How efficiently it compounds
ROIC
Weak · Struggling to earn much on the capital it uses
6.4%
ROE
Needs attention · Unfavorable
7.6%
Debt / equity
Favorable · 0.37 - strong leverage
0.53x
Current ratio
Strong · Comfortable room to cover bills due within a year
1.65x
Peer Comparison
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $142.32B | 36.0 | +4.6% | 56 |
 | $11.53B | 22.0 | +19.7% | 78 |
 | $4.60B | 13.9 | +13.5% | 77 |
 | $33.87B | 35.4 | +15.5% | 77 |
 | $1.11T | 40.1 | +49.6% | 76 |